KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Retained Earnings: 2019-2024

Historic Retained Earnings for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $2.8 billion.

  • Royalty Pharma's Retained Earnings fell 16.65% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year decrease of 16.65%. This contributed to the annual value of $2.8 billion for FY2024, which is 13.03% up from last year.
  • Latest data reveals that Royalty Pharma reported Retained Earnings of $2.8 billion as of FY2024, which was up 13.03% from $2.5 billion recorded in FY2023.
  • Royalty Pharma's Retained Earnings' 5-year high stood at $2.8 billion during FY2024, with a 5-year trough of $1.9 billion in FY2020.
  • For the 3-year period, Royalty Pharma's Retained Earnings averaged around $2.4 billion, with its median value being $2.5 billion (2023).
  • As far as peak fluctuations go, Royalty Pharma's Retained Earnings tumbled by 32.02% in 2020, and later increased by 28.14% in 2023.
  • Over the past 5 years, Royalty Pharma's Retained Earnings (Yearly) stood at $1.9 billion in 2020, then climbed by 17.42% to $2.3 billion in 2021, then decreased by 12.88% to $2.0 billion in 2022, then rose by 28.14% to $2.5 billion in 2023, then increased by 13.03% to $2.8 billion in 2024.